NCT05858619 Molecular Signatures of Cutaneous Dupilumab Response
| NCT ID | NCT05858619 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of California, San Francisco |
| Condition | Atopic Dermatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2028-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 15 participants in total. It began in 2023-02-01 with a primary completion date of 2028-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older 2. atopic dermatitis with a EASI (Eczema Area and Severity Index (EASI)) score of ≥7 Exclusion Criteria: 1. Known pregnancy 2. Known immunodeficiencies 3. Known parasitic infection -
Contact & Investigator
Jeffrey Cheng, MD, PhD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05858619 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05858619 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05858619 currently recruiting?
Yes, NCT05858619 is actively recruiting participants. Contact the research team at rashes@ucsf.edu for enrollment information.
Where is the NCT05858619 trial being conducted?
This trial is being conducted at San Francisco, United States.
Who is sponsoring the NCT05858619 clinical trial?
NCT05858619 is sponsored by University of California, San Francisco. The principal investigator is Jeffrey Cheng, MD, PhD at University of California, San Francisco. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.